Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00215943 · ClinicalTrials.gov registry record · Phase 3
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
A Phase 3 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT00215943 is a Phase 3 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 90 participants.
The verdict
NCT00215943, a Phase 3 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
Investigators planned to accrue 176 participants, to compare the response rate, overall response rate and survival of patients with multiple myeloma (MM) when randomized to two regimens (thalidomide+Dexamethasone versus Vincristine+Adriamycin+Dexamethasone). Investigators also planned to test if treatment with zoledronate immediately prior to chemotherapy results in an enhanced response to treatment (i.e. increase in complete response rates).
Interventions
- DRUG dexamethasone
- DRUG vincristine
- DRUG thalidomide
- DRUG zoledronic acid
- DRUG adriamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2003-06 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00215943
The ClinicalTrials.gov registry entry for NCT00215943 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which dexamethasone is the first listed.
NCT00215943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00215943 about?
NCT00215943 is a clinical study titled "Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)". Investigators planned to accrue 176 participants, to compare the response rate, overall response rate and survival of patients with multiple myeloma (MM) when randomized to two regimens (thalidomide+Dexamethasone versus Vincristine+Adriamycin+Dexamethasone). Investigators also planned to test if tre...
What is the current status of trial NCT00215943?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2003-06. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00215943?
The interventions under investigation include: dexamethasone (DRUG), vincristine (DRUG), thalidomide (DRUG), zoledronic acid (DRUG), adriamycin (DRUG).
Who is sponsoring clinical trial NCT00215943?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.